



ATTORNEY DOCKET NO. VEOC.001.01US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Geuze, *et al.*

Serial No.: 09/011,167

Filed: 5 October, 1998

For: **CELL-DERIVED ANTIGEN PRESENTING  
VESICLES**

)  
) Examiner: Amy DeCloux  
)  
) Art Unit: 1644  
)  
)  
) **STATEMENT UNDER**  
) **37 CFR §1.125(b)**  
)

**BOX AF**

Assistant Commissioner of Patents  
Washington, D.C. 20231

Sir:

Pursuant to 37 CFR §1.125(b), Applicant states that the content of the above-referenced application originally filed in the USPTO on 2 February, 1998 and the substitute specification filed on 27 October, 2000 are the same. Rearrangements made to the originally filed text to address the objections raised by the Examiner on page 3 of paper 13 are shown in the marked-up copy of the substitute specification submitted herewith.

Respectfully submitted,

Dated: 17 April, 2001

Jennifer L. Wahlsten  
Jennifer L. Wahlsten, Ph.D.  
Reg. No. 46,226

Rae-Venter Law Group, P.C.  
P.O. Box 60039  
Palo Alto, CA 94306  
Telephone: (650) 328-4400  
Facsimile: (650) 328-4477

BRV/JLW

**CERTIFICATE OF FIRST CLASS MAILING**

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231

on 4-17-01  
(date)

(Signature) [Signature]  
(Printed Name) Emilio Guerra

AMENDMENTS

Cancel Claim 2.

3. (Reiterated) The antigen presenting vesicle according to claim 13 further comprising at least partially processed antigens.
4. (Reiterated) The vesicle according to claim 3 wherein said at least partially processed antigens are presented in the context of MHC class I proteins.
6. (Reiterated) The antigen presenting vesicle according to claim 13, wherein said antigen presenting cell is derived from a B-lymphocyte, a Langerhans cell, a macrophage or a dendritic cell.
9. (Three Times Amended) [A method for obtaining antigen presenting vesicles] An antigen presenting vesicle having a membrane and a major histocompatibility complex (MHC) class I protein, [said method comprising] obtained by the step of:  
recovering a membrane-enriched fraction obtained by differential centrifugation of membrane-containing fractions of cell culture supernatants or lysates of antigen presenting cells [whereby fractions containing said antigen presenting vesicles are obtained].
- Not elected

Cancel Claim 10.

CERTIFICATE OF FIRST CLASS MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231

on 4-17-01  
(date)

(Signature)

(Printed Name)

Francis Owen

Amendments made to the Claims  
Serial No. 09/011,167

11. (Amended) [A method for obtaining antigen presenting vesicles] An antigen presenting vesicle having a membrane and a major histocompatibility complex [(MHC) protein derived from MHC] class I[I] molecule, [said method comprising] obtained by the step of:

recovering a 70,000 x g pellet obtained by differential centrifugation of membrane-containing fractions of cell culture media or lysates of antigen presenting cells containing MHC class I[I], whereby fractions containing said antigen presenting vesicles are obtained].

*Not elected*

12. (Amended) A [method for obtaining] purified antigen presenting vesicle[s] having a membrane and a major histocompatibility complex [(MHC) protein derived from MHC] class I[I] molecule, [said method comprising] obtained by the step of:

recovering a fraction having a buoyant density of 1.10 to 1.22 g/ml from a 70,000 x g pellet obtained by differential centrifugation of membrane-containing fractions of cell culture supernatants or lysates of antigen presenting cells containing MHC class I[I], whereby purified antigen presenting vesicles are obtained].

*Not elected*

13. (Twice Amended) An antigen presenting vesicle free from its natural surroundings, comprising:

a membrane and a major histocompatibility complex (MHC) class I protein or a functional derivative or fragment thereof, wherein said antigen presenting vesicle is obtainable from [a] an antigen presenting cell.

Add the following new claim:

14. (New) The antigen presenting vesicle according to Claim 13, wherein said vesicle does not contain a transferrin receptor.

*NEW*